AbCellera and Kodiak Sciences Collaborate to Develop Antibody Therapeutics for Eye Disorders

November 4, 2020
Pharmaceutical Technology Editors

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter 11-04-2020, Volume 15, Issue 11

The agreement will allow AbCellera to utilize its full stack, artificial intelligence-powered antibody discovery technology to identify large panels of antibodies against designated targets from Kodiak.

AbCellera, a Canadian technology company, and Kodiak Sciences, a US-based biopharmaceutical company, have entered into a partnership to develop therapeutic antibody candidates for use in ophthalmological disorders. Financial terms were not disclosed.

Through the collaboration, AbCellera will obtain research and development payments and will be eligible for downstream milestone payments, royalties, and net sales, an Oct. 29, 2020 press release said. The agreement will allow AbCellera to utilize its full stack, artificial intelligence-powered antibody discovery technology to identify large panels of antibodies against designated targets from Kodiak.

“Kodiak was one of AbCellera’s very first partners, and we are proud to expand our collaboration to support their innovative team in the fight against retinal diseases that cause blindness,” said Carl Hansen, PhD, president, and CEO of AbCellera, in the press release. “We are committed to making state-of-the-art antibody discovery broadly available to partners, empowering them to bring new therapies to patients quickly.”

“In our previous work with AbCellera, they delivered quality therapeutic antibody candidates with unique epitope and bioactivity behaviors that were advanced for clinical development. We have been impressed with the growth and power of their platform, both the biology-driven as well as the software-driven aspects. We are delighted to work with their experienced and dedicated team again,” added Victor Perlroth, MD, CEO of Kodiak Sciences, in the press release. “The value AbCellera brings to us as a partner is not only their state-of-the-art technology but also their expertise in working with us to discover superior and diverse therapeutic antibody candidates for novel disease targets.”

Source:AbCellera